Our Pricing

Weight Loss Injection Treatment UK: Compare Mounjaro, Wegovy & Saxenda

Published on: June 03, 2026

Looking for weight loss injection treatment UK online with transparent pricing and fast access? At Cured Pharmacy, you can access clinically proven treatments like Mounjaro, Wegovy, and Saxenda through a free online consultation with UK-registered prescribers, with discreet delivery direct to your door.

How Weight Loss Injections Work

Weight loss injections approved in the UK belong to a class of medications called GLP-1 receptor agonists, which mimic natural hormones that regulate appetite and blood sugar levels [1]. These treatments work by slowing gastric emptying, reducing hunger signals to the brain, and improving insulin sensitivity, helping patients achieve sustained weight reduction when combined with lifestyle changes.

The newest generation includes tirzepatide (Mounjaro), which uniquely activates both GLP-1 and GIP receptors simultaneously [2]. This dual-action mechanism has demonstrated superior weight loss outcomes in clinical trials compared to single-pathway alternatives, with participants in the SURMOUNT-1 trial achieving average reductions of up to 22.5% of their starting body weight over 72 weeks [2].

Traditional GLP-1 treatments like semaglutide (Wegovy) and liraglutide (Saxenda) remain highly effective options licensed by the MHRA. In the STEP trials, semaglutide produced average weight reductions of 14.9% over 68 weeks, whilst liraglutide achieved 8% reductions in the SCALE trials [1][3]. Your UK prescriber will assess which treatment aligns with your medical history, weight loss goals, and individual response factors.

Mounjaro (Tirzepatide): The Dual-Action Option

Mounjaro represents the latest advancement in weight management medication, licensed in the UK for adults with a BMI of 30 or above, or 27 with weight-related health conditions [2]. As the first dual GIP/GLP-1 receptor agonist, it activates two complementary pathways that regulate metabolism and appetite control, producing clinical outcomes that exceed earlier single-pathway treatments.

Clinical evidence from the SURMOUNT trials demonstrates Mounjaro's efficacy across diverse patient populations. Participants receiving the 15mg maintenance dose achieved average body weight reductions of 22.5% over 72 weeks, with 91% of patients losing at least 5% of their starting weight [2]. The treatment follows a gradual dose escalation protocol, starting at 2.5mg weekly and increasing every four weeks to minimise gastrointestinal side effects whilst optimising therapeutic response.

At Cured Pharmacy, Mounjaro is available with transparent upfront pricing and includes a comprehensive clinical assessment by UK prescribers. The once-weekly injection schedule offers convenience compared to daily alternatives, and the KwikPen delivery system simplifies self-administration at home.

Who Can Use Mounjaro?

Mounjaro is suitable for adults who meet specific clinical criteria established by NICE guidance. You may be eligible if you have a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. Your prescriber will review your complete medical history, current medications, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before approving treatment.

Wegovy (Semaglutide): Proven Clinical Results

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been extensively studied in weight management and was the first treatment of its kind licensed specifically for obesity in the UK [1]. The medication works by mimicking the hormone GLP-1, which naturally regulates appetite and food intake, helping patients feel fuller for longer periods and reducing caloric consumption.

The STEP clinical trial programme demonstrated Wegovy's effectiveness across multiple patient populations. In STEP 1, participants receiving 2.4mg weekly semaglutide achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [1]. Notably, 83.5% of patients on Wegovy lost at least 5% of their body weight, and 66.1% achieved reductions exceeding 10% — thresholds associated with significant improvements in cardiovascular risk factors and metabolic health markers [3].

Wegovy follows a structured dose escalation schedule, beginning at 0.25mg weekly and increasing gradually over 16 weeks to the maintenance dose of 2.4mg. This approach minimises common gastrointestinal side effects such as nausea and allows the body to adapt to the medication's effects. The once-weekly injection is administered subcutaneously using a pre-filled pen, and most patients find the routine manageable within their weekly schedule.

Wegovy vs Mounjaro: Key Differences

Both treatments are administered as once-weekly injections and share similar mechanisms targeting appetite regulation, but they differ in their receptor activity and clinical outcomes. Mounjaro activates both GIP and GLP-1 receptors, whilst Wegovy targets only GLP-1 receptors [2]. Head-to-head trials suggest tirzepatide produces greater average weight reductions, though individual responses vary based on metabolic factors, adherence, and lifestyle modifications. Your UK prescriber will recommend the most appropriate option based on your medical profile, treatment history, and cost considerations.

Saxenda (Liraglutide): Daily Injection Alternative

Saxenda contains liraglutide, a GLP-1 receptor agonist that was among the first medications licensed in the UK specifically for weight management in adults with obesity [3]. Unlike the once-weekly options, Saxenda requires daily subcutaneous injection, which some patients prefer as it allows for more flexible dose adjustments and quicker onset of appetite-suppressing effects.

Clinical trials including the SCALE programme demonstrated that liraglutide 3mg daily produced average weight reductions of 8% over 56 weeks, with 63.2% of participants losing at least 5% of their starting weight [3]. Whilst the absolute weight loss is lower compared to newer weekly injections, Saxenda remains a valuable option for patients who prefer daily dosing or have contraindications to other GLP-1 treatments.

The treatment begins at 0.6mg daily and increases weekly by 0.6mg increments until reaching the maintenance dose of 3mg. This gradual escalation helps minimise gastrointestinal side effects, which are the most commonly reported adverse events. Saxenda is suitable for adults with a BMI of 30 or above, or 27 with weight-related health conditions, subject to prescriber assessment and approval.

Orlistat Capsules: Non-Injection Weight Loss Option

For patients who prefer oral medication or have contraindications to injectable treatments, orlistat offers an alternative mechanism for weight management. Unlike GLP-1 receptor agonists that work centrally on appetite pathways, orlistat acts locally in the digestive system by inhibiting pancreatic lipase enzymes, preventing approximately 30% of dietary fat from being absorbed [5].

Orlistat is available in two strengths: 120mg prescription-only capsules (Orlistat, Xenical) and 60mg over-the-counter formulations (Alli, Orlos). Clinical trials demonstrate that orlistat 120mg three times daily, combined with a reduced-calorie diet, produces average weight reductions of 5-10% over 12 months [5]. The medication is most effective when dietary fat intake is distributed evenly across three main meals and does not exceed 30% of total daily calories.

Common side effects relate to the medication's mechanism and include oily stools, flatulence, and faecal urgency, particularly when dietary fat intake is excessive. These effects typically diminish as patients adapt their eating patterns. Orlistat is suitable for adults with a BMI of 28 or above and requires clinical assessment to ensure appropriate use and monitoring of fat-soluble vitamin levels during prolonged treatment.

Choosing Between Injectable and Oral Treatments

Injectable GLP-1 treatments generally produce greater weight reductions and target appetite regulation directly, whilst orlistat requires stricter dietary compliance and works through fat malabsorption. Your UK prescriber will consider factors including your weight loss goals, medical history, tolerance for injections, dietary habits, and any contraindications when recommending the most suitable treatment. Many patients achieve optimal results by combining medication with structured dietary changes and increased physical activity, regardless of which treatment type they use.

How to Access Weight Loss Injection Treatment at Cured Pharmacy

Accessing prescription weight loss treatments through Cured Pharmacy involves a straightforward online process designed to meet MHRA and GPhC regulatory requirements whilst providing convenience and discretion. The entire consultation typically takes under three minutes and can be completed from your smartphone, tablet, or computer at any time that suits your schedule.

Begin by selecting your preferred treatment and clicking 'Start Assessment' to access the online clinical questionnaire. You'll provide information about your medical history, current medications, weight management goals, and any previous experience with weight loss treatments. This information is reviewed by UK-registered prescribers who assess your suitability based on current NICE guidance and prescribing protocols [4]. If approved, your prescription is issued electronically and sent directly to our dispensing team.

Your medication is dispensed by our UK-registered pharmacy team under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and dispatched in 100% discreet packaging with no external branding. Most orders are delivered within 2-3 working days via tracked courier service. You'll receive clear instructions on injection technique, dose escalation schedules, and side effect management, along with access to ongoing clinical support throughout your treatment journey.

Transparent Pricing and Ongoing Support

At Cured Pharmacy, all treatment prices are displayed upfront before you begin your consultation, with no hidden fees or surprise charges. Our lowest price guarantee ensures you're accessing competitive UK pricing for genuine licensed medications. Repeat prescriptions can be managed through your online account, and our clinical team remains available to address questions or concerns as your treatment progresses. All prescription medications require ongoing prescriber approval, and your UK clinician will review your progress at appropriate intervals to ensure treatment remains safe and effective for your individual circumstances.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.